Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
The company's need to find another growth story is laid bare by a setback to its label expansion plans for Cabometyx.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.